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SummarY
introduction. Very few epilepsy phenotypes have been associated with causative genes; nevertheless, it is 
becoming possible, for some epilepsy phenotypes, to predict the most efficacious anti-epileptic drugs for 
patients based on their genetic makeup. The development of individualized medicine based on genetic infor-
mation and the genetic diagnosis of epilepsy are expected to greatly improve the diagnosis and treatment of 
epilepsy. Here, we developed a DNA array (resequencing array) for the genetic diagnosis of epilepsies in which 
14 epilepsy – related genes (SCN1A, SCN1B, CHRNA4, CHRNA7, CHRNB2, GABRA1, GABRD, GABRG2, CACNB4, CLCN2, 
KCNQ2, KCNQ3, CACNA1A, and CACNA1H) have been mounted.
aim. The aim of the present study is to evaluate the performance of our custom array in detecting the SCN1A 
mutations in patients with severe myoclonic epilepsy in infancy.
material and methods. We compared mutation data generated by DNA array sequencing of DNA samples 
from patients with severe myoclonic epilepsy in infancy to the data generated by capillary sequencing.
results. Heterozygosity was detected in 44 of 48 patients (92%). We successfully identified epilepsy mutations, 
and the results of DNA array analyses were largely consistent with the results of capillary sequencing analysis.
conclusion. These findings indicate that this DNA array is likely to be a useful tool in clinical settings.
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6Background
Since the first responsible gene for idiopathic epilep-
sy, CHRNA4, was identified in a patient with autoso-
mal dominant nocturnal frontal lobe epilepsy in 1995 
(Steinlein et al., 1995), at least a further 25 genes have 
been identified as epilepsy-related genes (Reid et al., 
2009; Ottman et al., 2010). Most encode voltage-gated 
ion channels (Na+, K+, Ca2+, and Cl−) or ligand-gated 
channels (nicotinic acetylcholine and GABAA recep-
tors). Causative mutations in these genes include mis-
sense/nonsense mutations that result from single-base 
substitution or deletion/insertion frame-shift muta-
tions. Microchromosomal deletions that cause the loss 
of multiple exons or the loss of a whole gene were also 
recently found to be associated with severe myoclonic 
epilepsy in infancy (SMEI) (Madia et al., 2006; Mulley 
et al., 2006; Suls et al., 2006; Wang et al., 2008; Saitoh 
et al., 2012). These various mutations are thought to 
cause some cases of idiopathic epilepsies, whereas other 
cases of epilepsy are caused by mutation of only a sin-
gle gene. Identification of mutated genes or loci in in-
dividual patients is an important step toward our ulti-
mate aim, which is the development of individualized 
pharmacotherapy for epilepsy.
The current treatment of epilepsy is mainly phar-
macotherapy with anti-epileptic drugs (AEDs), but this 
treatment is symptomatic and not a radical treatment. 
In general, the selection of AEDs is based on the types 
of seizures and trial and error, and 30% of patients with 
epilepsy do not achieve adequate seizure control from 
AED treatment (Kwan and Brodie, 2000). The aim of 
individualized medicine for epilepsy is to control sei-
zures by creating customized treatment approaches for 
each patient based on the patient’s genetic makeup This 
individualized approach is based on the belief that ge-
netic information can be used to improve the selection 
of an effective AED and assist in the determination of 
an appropriate dose. It is known that some genes cause 
pharmacoresistance (Nasir et al., 2011). However, the 
identification of genes associated with epilepsy is on-
going work, and it is obvious that more epilepsy-relat-
ed genes will be identified. Therefore, more efficient 
and cost-effective tools for the detection of individual 
known mutations in patients with epilepsy are needed.
aim
Here, we describe a custom resequencing array that 
can be used for high-throughputdetection of epilep-
sy-related mutations. This array can enable research-
ers and clinicians to detect both known and novel mis-
sense/nonsense mutations. The aim of the present study 
is to evaluate the performance of this custom array. We 
investigated the consistency of this array by compar-
ing results of resequencing SCN1A mutations (mis-
sense or nonsense mutations) with results from capil-
lary sequencing; all DNA samples were taken from pa-
tients with SMEI.
Material and Methods
Sample information
We investigated 89 patients with SMEI. Blood samples 
were collected from 46 SMEI patients who had missense 
or nonsense mutations of SCN1A that were identified by 
capillary sequencing. The array analyst was blind to the 
capillary sequencing data. Genomic DNA was extracted 
from peripheral white blood cells according to stand-
ard protocols. Two patients, S41 and S73, each carried 
two mutations in SCN1A; therefore, the total number of 
mutations was 48 (Table 1). Patients with SMEI develop 
apparently normally until their infancy, when the first 
seizure episode often is seen as generalized or unilateral 
tonic-clonic or clonic seizures induced by fever. The first 
attack of SMEI may be discernible from simple febrile 
seizures, and the seizure activity evoked by fever tends 
to be prolonged and could advance to status epilepti-
cus. Patients subsequently manifest a variety of seizure 
types, including atypical absence, myoclonic, and sim-
ple or complex partial seizures, which are generally re-
fractory. Seizures induced easily by high- and low-grade 
fever are common. Around the second year of life, psy-
chomotor delay becomes evident. Febrile seizures and/
or epilepsy are often seen in the family. Diagnosis was 
achieved according to well-described diagnosis crite-
ria (Dravet et al., 1992; Fukuma et al., 2004). Patients 
were diagnosed as having SMEI by epileptologists and 
neuropediatricians and registered with the Epilepsy 
Genetic Study Group, Japan. Informed consent was 
obtained from the parents of each patient with SMEI. 
This study was approved by the Ethics Committee of 
each participating institution.
Probe design for custom resequencing array
Custom-designed resequencing microarrays consist of 
a high density of 25-mer oligonucleotide probes synthe-
sized on the array by photolithography and solid-phase 
DNA synthesis for hybridization-based analysis of spe-
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cific sequences of interest (Hacia, 1999). Affymetrix 
technology demonstrates high performance in mi-
croarray quality control study (coefficient variations 
was under 10% within facility) (Shi et al., 2006). This 
custom resequencing array (169 format) was designed 
for detecting mutations from patients with a diagno-
sis of epilepsy. Based on previous reports of mutation 
information from patients with epilepsy, sequences 
from 54 regions of 14 epilepsy-related genes (SCN1A, 
SCN1B, CHRNA4, CHRNA7, CHRNB2, GABRA1, 
GABRD, GABRG2, CACNB4, CLCN2, KCNQ2, KCNQ3, 
CACNA1A, and CACNA1H) were tiled on the array; 
the first and last 12 flanking bases of each region were 
included in the sequences. Table 2 lists the names, re-
gions, and lengths of the tiled gene sequences; the NCBI 
accession numbers; and the locus start and end sites. 
Repetitive regions, which lead to cross hybridization, 
were removed by using RepeatMasker (http://www.re-
peatmasker.org/). Mutations in SCN2A and CHRNA2, 
which are also candidate epilepsy-related genes, were 
found in exons 2, 4, 5, 15, 16, 20, 21, 26, and 27 of 
SCN2A and exon 6 of CHRNA2 in DNA samples from 
the patients with epilepsy. However, these two genes 
share highly homologous sequences with SCN1A and 
CHRNA4, respectively; therefore SCN2A and CHRNA2 
were excluded from the array to avoid cross hybridi-
zation. The sequences arrayed on the chip consisted 
of 17,580 bp and represented approximately 91% of all 
known epilepsy-related regions. In addition, 38 to 47 
bp of sequences representing 24 known insertion or de-
letion sites were tiled on the array to detect known de-
letion/ insertion mutations that cause epilepsy. Table 3 
lists the sites, sequences, and lengths of each deletion/
insertion. We designated this custom-designed array 
as the EpiGene.
Primers and Pcr conditions
PCR primers were designed to amplify each sequence 
tiled on the array. As shown in Table 4, PCR was per-
formed with 48 primer sets under five PCR condi-
tions. For conditions 1–4, the reaction consisted of 0.3 
U KOD FX (Toyobo), 15 ng of genomic DNA, 7.5 mL of 
2x KOD FX buffer, 3 mL of dNTPs (2 mM), and 6 pmol 
of each primer for a total reaction volume of 15 mL. For 
condition 5, the reaction consisted of 0.6 U KOD Plus 
(Toyobo), 3 mL of 10x buffer, 3 mL of dNTPs (2 mM), 
12 pmol of each primer, and 30 ng of genomic DNA for 
a total reaction volume of 30 mL. All PCRs began with 
a 2-min incubation at 94°C to denature the duplexes; 
Sample no. mutation results
S1 c.4547C>A C
S4 c.4064T>C C
S6 c.2837G>A C
S7 c.5734C>T C
S8 c.302G>A C
S10 c.2134C>T C
S12 c.5674C>T C
S14 c.2802G>C I
S15 c.568T>C C
S16 c.2855G>A C
S21 c.2802G>A C
S25 c.2134C>T C
S26 c.2831T>C C
S30 c.2243G>A I
S31 c.2134C>T C
S34 c.3373G>T I
S35 c.4384T>C C
S38 c.4280A>C C
S39 c.4573C>T C
S41 c.251A>G C
c.4723C>T C
S42 c.4664T>G C
S47 c.1277A>G C
S50 c.4032T>G C
S53 c.4633A>G C
S54 c.5734C>T C
S55 c.1150T>C C
S58 c.4573C>T C
S59 c.3075T>G I
S60 c.2584C>T C
S62 c.2134C>T C
S63 c.4507G>A C
S64 c.301C>T C
S69 c.251A>G C
S70 c.2819C>T C
S72 c.4358A>G C
S73 c.680T>G C
c.4723C>T C
S74 c.5051A>C C
S76 c.4823A>G C
S78 c.1087A>C C
S79 c.5542C>T C
S80 c.535T>C C
S82 c.4679T>A C
S84 c.5674C>T C
S86 c.1277A>G C
S87 c.58G>T C
S88 c.1150T>C C
Table 1. Comparison of resequencing results on SCN1A 
mutations with results from capillary sequencing data
C = consistent; I = inconsistent
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Table 2. Probe information 1
gene Sequence region tiled on the array length 
(bp)
ncBi accession 
number
locus (start) locus (end)
Sodium channel SCN1A exon1 290 NT_005403.16 17139562 17139273
Voltage-gated, type I, alpha subunit SCN1A exon2 145 NT_005403.16 17124629 17124485
SCN1A exon3 116 NT_005403.16 17122428 17122313
SCN1A exon4 155 NT_005403.16 17120707 17120553
SCN1A exon5 118 NT_005403.16 17118884 17118767
SCN1A exon6 296 NT_005403.16 17117929 17117634
SCN1A exon7 90 NT_005403.16 17114890 17114801
SCN1A exon8,intron8 and exon9 1025 NT_005403.16 17113709 17112685
SCN1A exon10 311 NT_005403.16 17111268 17110958
SCN1A exon11 407 NT_005403.16 17109990 17109584
SCN1A exon12 159 NT_005403.16 17108365 17108207
SCN1A exon13 265 NT_005403.16 17107410 17107146
SCN1A exon14 200 NT_005403.16 17105537 17105338
SCN1A exon15 383 NT_005403.16 17104073 17103691
SCN1A exon16 509 NT_005403.16 17102471 17101963
SCN1A exon17 147 NT_005403.16 17081668 17081522
SCN1A exon18 and 5bp of intron18 5’-region 186 NT_005403.16 17079839 17079654
SCN1A exon19 200 NT_005403.16 17078223 17078024
SCN1A exon20 149 NT_005403.16 17075782 17075634
SCN1A exon21 308 NT_005403.16 17068694 17068387
SCN1A exon22 and 1bp of intron22 5’-region 80 NT_005403.16 17065717 17065637
SCN1A exon23 164 NT_005403.16 17064116 17063953
SCN1A exon24 131 NT_005403.16 17062058 17061928
SCN1A exon25 298 NT_005403.16 17060357 17060061
1197bp of SCN1A exon26 5’-region 1197 NT_005403.16 17058363 17057167
2084bp of SCN1A exon26 3’-region 2084 NT_005403.16 17057162 17055078
Sodium channel, voltage-gated, type I, beta subunit SCN1B exon3 267 NT_011109.15 7792608 7792874
Neuronal nicotinic acetylchorine receptor α4 subunit CHRNA4 exon5 1401 NT_011333.5 719022 717622
Neuronal nicotinic acetylchorine receptor α7 subunit CHRNA7 exon10 545 NT_010194.16 3250685 3251229
Neuronal nicotinic acetylchorine receptor β2 subunit CHRNB2 exon5 999 NT_004487.18 5034007 5035005
γ-aminobutyric acid receptor subtype A (GABAA) α1 subunit GABRA1 exon10 229 NT_023133.12 6132217 6132445
γ-aminobutyric acid receptor subtype A (GABAA) δ subunit GABRD exon5 109 NT_004350.18 1437632 1437740
GABRD exon6 164 NT_004350.18 1438210 1438373
γ-aminobutyric acid receptor subtype A (GABAA) γ2 subunit GABRG2 exon2 178 NT_023133.12 6330379 6330556
γ-aminobutyric acid receptor subtype A (GABAA) γ2 subunit GABRG2 exon4 247 NT_023133.12 6334189 6334435
Calcium channel, voltage-dependent, beta 4 subunit CACNB4 exon3 146 NT_005403.16 2949315 2949170
CACNB4 exon13 212 NT_005403.16 2908033 2907822
Cloride channel 2 CLCN2 exon5 160 NT_005612.15 90571046 90570887
CLCN2 exon19 100 NT_005612.15 90565761 90565662
Potassium voltage-gated channel, KQT-like subfamily, member 2 105bp of KCNQ2 exon1 5’- region 105 NT_011333.5 840634 840530
361bp of KCNQ2 exon1 3’-region 361 NT_011333.5 840499 840138
KCNQ2 exon2 117 NT_011333.5 814833 814717
KCNQ2 exon8 121 NT_011333.5 801899 801779
Potassium voltage-gated channel, KQT-like subfamily, member 3 KCNQ3 exon5 182 NT_008046.15 46406047 46405866
Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CACNA1A exon3 166 NT_011295.10 4826644 4826479
CACNA1A exon33 92 NT_011295.10 4608903 4608812
CACNA1A exon36 154 NT_011295.10 4603838 4603685
Calcium channel, voltage-dependent, T type, alpha 1H subunit CACNA1H exon4 160 NT_037887.4 1185420 1185579
CACNA1H exon7 342 NT_037887.4 1190244 1190585
368bp of CACNA1H exon9 5’-region 368 NT_037887.4 1191651 1192018
437bp of CACNA1H exon9 3’-region 437 NT_037887.4 1192029 1192466
CACNA1H exon10 475 NT_037887.4 1193998 1194472
CACNA1H exon11 178 NT_037887.4 1195102 1195279
CACNA1H exon23 152 NT_037887.4 1201469 1201620
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Table 3. Probe information 2 (deletion/insertion)
insertion/deletion mutation site length (bp) †Sequence (5’-3’) reference
CHRNA4_ins776GCT 47 GCTGTCGCTCACCGTCTTCCTGCTGCTCGCTATCACCGAGATCATCC (Steinlein et al., 1997)
KCNQ2_del314TCC 38 CGTGTTCCTCCTGGTTTTC*TGCCTCGTGCTGTCTGTGT (Claes et al., 2004)
SCN1A_del429GT 42 CACTATTTTGACAAACT*GTGTTTATGACAATGAGTAACCCTC (Fukuma et al., 2004)
SCN1A_del657AG 42 CTCGGCATTGAGAACATTCAG*TTCTCCGAGCATTGAAGACGA (Claes et al., 2001)
SCN1A_del853CTTC 42 TACAATGGCCTCCCACCAATGCTT*GGAGGAACATAGTATAGA (Nabbout et al., 2003)
SCN1A_del1121C 42 CCTTCAGTTGGGCTTTTTTGTC*TTGTTTCGACTAATGACTCA (Nabbout et al., 2003)
SCN1A_del1502G 42 CTAAGGAAAGAAGAAATCGGAG*AAGAAAAGAAAACAGAAAGA (Ohmori et al., 2002)
SCN1A_ins1640A 43 GAACCGATTGACATATGAAAAAGAGGTACTCCTCCCCACACCA (Ohmori et al., 2002)
SCN1A_del1820C 42 ATAACGAGAGCCGTAGAGATTC*TTGTTTGTGCCCCGACGACA (Ohmori et al., 2002)
SCN1A_ins2118AA 44 TCCATGGACTTTCTAGAAGATAACCTTCCCAAAGGCAACGAGCA (Kearney et al., 2006)
SCN1A_del2740A 42 GTCGGCATGCAGCTCTTTGGTAAA*GCTACAAAGATTGTGTCT (Kearney et al., 2006)
SCN1A_del2835C 42 CCACTCCTTCCTGATTGTGTTC*GCGTGCTGTGTGGGGAGTGG (Fujiwara et al., 2003)
SCN1A_del3195TA 42 AGACAGTTGTATGTCCAATCA*CAGCAGAAATTGGGAAAGATC (Nabbout et al., 2003)
SCN1A_ins3298AA 44 AAAAATACATTATTGATGAAAAAGTGATTACATGTCATTCATAA (Claes et al., 2001)
SCN1A_del3524TT 42 TAGTGGAACCTGAAGAAACTC*GAACCAGAAGCTTGTTTCACT (Fukuma et al., 2004)
SCN1A_ins3643TA 43 AAGGACGTGTTTCCGAATAGTATTGAACATAACTGGTTTGAGA (Nabbout et al., 2003)
SCN1A_del3864CTT 42 CAATGCCTGGTGTTGGCTGGAC*TTAATTGTTGATGTTTCATT (Ohmori et al., 2002)
SCN1A_del5010GTTT 42 GATGATGTCCCTTCCTGCG*TTAACATCGGCCTCCTACTCTTC (Claes et al., 2001)
SCN1A_ins5239A 44 GACTGTGACCCTAATAAAGTTAAACCCTGGAAGCTCAGTTAAGG (Gennaro et al., 2003)
SCN1A_ins5291T 43 GAACCCATCTGTTGGAATTTTTCTTTTTTGTCAGTTACATCAT (Fujiwara et al., 2003)
SCN1A_del5414TT 42 AGCCTCTGAGTGAGGATGACT*GAGATGTTCTATGAGGTTTGG (Nabbout et al., 2003)
SCN1A_del5657G 42 GTGGAGAGATGGATGCTCTAC*AATACAGATGGAAGAGCGATT (Nabbout et al., 2003)
SCN1A_del5668G 42 GATGCTCTACGAATACAGATG*AAGAGCGATTCATGGCTTCCA (Nabbout et al., 2003)
SCN1A_del5711ATCA 42 CCAATCCTTCCAAGGTCTCCT*GCCAATCACTACTACTTTAAA (Sugawara et al., 2001)
†* = deletion site;  _ = insertion site
the denaturation was followed by 30 cycles of each con-
dition shown in Table 4. PCR products were subjected 
to electrophoresis on a 1% agarose gel to confirm that 
bands of the appropriate sizes were present.
Quantitation, pooling, and fragmentation
The following steps were performed according to the 
manufacturer’s instructions. To pool each PCR prod-
uct with other products of the same molecular weight 
(111.7 pM/array), PCR products were quantitated 
by using a Quant-iT™ PicoGreen dsDNA Assay kit 
(Invitrogen) and a microplate reader (MTP-601Lab, 
Corona). Pooled samples were purified by using the 
DNA Amplification Clean-Up Kit (Clontech), and 
230-ng pooled samples were fragmented with a frag-
mentation reagent (Affymetrix). Fragmentation reac-
tion mixtures were incubated at 37°C for 35 min to let 
the reactions proceed, and then at 95°C for 15 min to 
inactivate the fragmentation reagent. Samples of frag-
mented DNA (2 mL each) were subjected to electro-
phoresis on 20% TBE polyacrylamide gels to ensure 
that an optimal range of fragment sizes (20 to 200 bp) 
was achieved.
labeling and hybridization
Fragmented samples were labeled with biotin at the 
3’-end by using terminal deoxynucleotidyl transferase 
and labeling reagent (Affymetrix) according to the 
manufacturer’s instructions. The reaction mixtures 
were incubated at 37°C for 120 min followed by heat in-
activation at 95°C for 15 min. Prehybridization of each 
array was achieved by the addition of 80 mL of prehy-
bridization buffer (10 mM Tris, pH 7.8, 0.01% Tween 
20), followed by 15 min of rotation (60 rpm) at 49°C 
in a Gene Chip hybridization oven 640 (Affymetrix). 
Labeled samples were added to 72 mL of hybridization 
master mix (3 M tetra methyl ammonium chloride, 
10 mM Tris pH 7.8, 0.01% Tween 20, 500 mg/mL acety-
lated BSA, 100 mg/mL herring sperm DNA) to a final 
volume of 98.9 mL. This hybridized cocktail was de-
natured at 95°C for 5 min and equilibrated at 49°C for 
5 min. Prehybridization buffer was removed from the 
arrays and replaced with 80 mL of hybridized cocktail; 
then, the arrays were subjected to rotation (60 rpm) for 
16 h at 49°C. Arrays were washed and stained by using 
the “Mini_DNA array_WS5_450” protocol of Fluidic 
Station 450 and then scanned on a GeneChip scanner 
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Table 4. PCR conditions
amplified region length (bp) Forward Primer (5’-3’) reverse Primer (5’-3’)
PCR condition 1 SCN1A exon3 361 ATC AGT ATA ACG CCA GCA GG TTG GCT AAG CTG CAG TTT G
98°(10sec)-58° SCN1A exon4 371 CAT AAG CAC TGA TGG AAA ACC CTC TTT GTG TTA GGA AGC TGA A
KOD FX (Toyobo) SCN1A exon5 361 AAA CTC CAA GGC TGA TAA AG TTC GGT AAT TCC AGG TAA GA
SCN1A exon12 296 ATG CAC TAT TCC CAA CTC ACA CCA TTT GGT TGT TTG CTT GTC 
SCN1A exon17 351 TAA ACA AGC TGC ACT CCA AA GGG TTA GCA CAG ACA ATG AT
GABRA1 exon10 375 TTC AAG TAG GCT GTC CCA T CAT ACT CCA TCC AAT ACC ACA
GABRG2 exon2 310 TGG TCT GTG GAT AAA AGT CAA C TTG CTC TTG AAC TAC ACT GAT G
CACNB4 exon3 286 TGA GCA ACG ACC CAC TTT CAT GGA GTG TGT GCA TCA
CACNB4 exon13 395 GTC TCC ATC CTA ATC AAG TTC C GCC CAT ATA GCA CCT CAA AT
CLCN2 exon5 277 TCT TCC ACC AGG AGG GAC T CCT CAG GCT GTC GGT ATG TT
CLCN2 exon19 219 GGT TAA TGA CGT GGT CTC A CTT ACC TTT CCT GGT CCT CTC
KCNQ2 exon2 247 AAC AGG AAC GGA AGA CAG AC TCC TGA GTT CTG GAG ACA CA
KCNQ2 exon8 318 TGA AAC AGT TGC TTG GTG G ACA GAG GGT AAA CTG AGG CTG
KCNQ3 exon5 285 CCT CCA CCT CTC TCT GAC TCT T GCT CCA GCA TCC ACT CAA C
CACNA1A exon3 274 CAC CAA CCA AAA GCC TCG TA GCT GGT TCC CTG ATC TTG TC
CACNA1A exon33 219 TGA ACC AGG CTC CTC TGA C CAA GGG AGG AAG ACA GTG C
CACNA1A exon36 233 GGA GAG GTG AGT ATT GTG GCT CAC TCA TTC ATT CCC TCG GT
CACNA1H exon4 287 TGA GCT GAG CTG TTC CAC CCT CTA GAA CAC ACC TCC CAT
PCR condition 2 SCN1A exon1 574 AGT AGG CAA TTA GCA GCA A CCT GTA TCA GTA AAG CAC AAG A
98°C (10sec)-58°C SCN1A exon2 600 AGA TGG TAG AGG TAA ACA TGG T GAA GAG ATC CAG TGA CAG TTT G
KOD FX (Toyobo) SCN1A exon6 589 AGC CCC TCA AGT ATT TAT CCT CTT CCA TTA CTC TAT CTC GAC A 
SCN1A exon7 773 ATA GTG CTG CAA TGA ACA TAC G GCG AGA GGA CCA GAA AAT ATA C 
SCN1A exon8-exon9 1085 ACG ATA AAA GGT CAG TGC CA AAA GGC AGC AGA ACG ACT
SCN1A exon10 478 TAA CTA TGT GAA GAA GGG ATG G CAG TCT CTT CAG GTG CTA TGT T 
SCN1A exon11 700 ATC ATT CTC AAG GTT GCC GT AGG TTG CAA TCT ATC TCC TCA T
SCN1A exon13 543 TGA AGG ATG GTT GAA AGA CTG TGT TAC CTG GGC TCT ATG TGT
SCN1A exon14 434 TGC AAG AAC CCT GAT TGT TAG TAT CTA CTT CGC GTT TCC ACA 
SCN1A exon15 526 GTG CCA TGC TGG TGT ATT TC CGG TTA GGG CAG ATC AGA TAT T
SCN1A exon16 763 GCC CAG CAT GAG AGT ATA TTG TGC TCT TCC CTA CAT TGG TG
SCN1A exon20 807 AAC TCC CAA GAT GGA TTA GG CAC AGT AGA AAC TTC CTG CTT 
SCN1A exon21 518 CAT CTG GGC TCA TAA ACT TG AGA CCA GAG ATT ACT AGG GGA A
SCN1A exon24 412 GTG AGA CAA GCA TGC AAG TT TGA GAT TTG GGG GTG TTT G
SCN1A exon25 482 TTG CTG GGA TGA TCT TGA AT TAC AAA AAT CAG GGC CAA TG 
SCN1B exon3 416 AGC CCA TCT GTG TGC CAT TGT CCC TCC ATC TGG CTC T
CHRNA7 exon10 599 TCA GGG CTG CTC TTA ACG CCT TGC CCA TCT GTG AGT
CHRNB2 exon5 1118 GGT TGA TGG GTA AGG AGG AAG TAT AGA ACG CCG CTG CTT T 
GABRG2 exon4 703 TGG GTG AGA CAG TAA CCT CC GCA AAG CGT AGG TGC AAA G
KCNQ2 exon1 748 CGC TGT ACA ATC GCT CTC C CTC CCC TCT CCT TCG ACT 
CACNA1H exon7 538 CCC TGA CCC TGA TTG TAC CT TGA TGT CCA CCC AGC CTT 
CACNA1H exon9 906 CGC TCA CTC ACT GCC ACT T GAA TGA CAC ACC GGA GAC C
CACNA1H exon10 632 GCT CCT GTG TGT GAG GGT TC CCT ACC ATC AGG TCA GGC A
CACNA1H exon23 445 CTG CTG CGC CTT CTT CAT TCA CTG GCG AGG GTT AGA
PCR condition 3 SCN1A exon18-exon19 1941 AAG CTA CCT TGA ACA GAG ACA TAG CAA GAC AGA GAT GAG CAT A
98°C (10sec)-58°C SCN1A exon22-exon23 2030 CTC ATT TGG CAG AGA AAA CAC GGG AGG ATA TAT CAA ATG GC
KOD FX (Toyobo)
PCR condition 4 CHRNA4 exon5 1696 ACC AGG AAG AAA GGG CGT AAT GCC TCT GTG TGT GGA C
98°C (10sec)-68°C GABRD exon5-exon6 1024 GTC TGA GAA GTA GCT GGG GCT TTC CTA AGG CAG CAG CGT 
KOD FX (Toyobo) CACNA1H exon11 586 CCA AAC CTG CTC CCA GAT TGC CAG AGA GTG GAG CTT C
PCR condition 5 SCN1A exon26 3387 CCT TCT CCC CCA ATT TGT AA CGC ATG ATT TCT TCA CTG GT
94°C (15sec)-58°C
KOD plus (Toyobo)
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(GCS 3000). The data were analyzed by using the Gene 
Chip Operating Software to obtain signal intensity data 
and by using the GeneChip Sequence Analysis Software 
(ver. 4.0) to generate sequence base calls. We used the 
default set points, with the exception of a quality score 
threshold of “0” and a genome model of “0”.
results
The EpiGene identified 48 SCN1A mutations in DNA 
samples from patients with SMEI, and 44 of these mu-
tations were consistent with mutations identified by us-
ing capillary sequencing (Table 1). Heterozygosity was 
identified in 92% of all cases. No SCN1A mutations were 
found in 125 control samples from healthy volunteers 
without epilepsy. The call rate was 95%; overall accura-
cy was > 99%; and the false-positive rate was 1.1%. Two 
patients (S41 and S73) had two mutations, and it is un-
known which of the two mutations is related to epilep-
sy. Our results indicate that SCN1A mutations can be 
correctly identified by using the EpiGene. Analyses of 
other genes tiled on the EpiGene are currently ongoing, 
and the results will be reported separately.
diScuSSion
SCN1A mutations are found in approximately 80% of 
SMEI patients. However, several different missense mu-
tations in SCN1A have been identified in epileptic pa-
tients with benign phenotypes (febrile seizures, SMEI 
borderlands). Several mutations of SCN1A show good 
response to AED treatment, even if the mutation was 
identified in SMEI (Kaneko et al., 2008). In such cases, 
the EpiGene will be applicable for screening purposes.
Resequencing arrays are new tools for the identification 
of mutation sites in patients with epilepsy. For high-
throughput detection of epilepsy-related mutations, 
we generated a custom resequencing array for detec-
tion of missense and nonsense mutations of SCN1A in 
SMEI patients, and the data generated by using this ar-
ray were suitable for use in clinical settings. However, 
the EpiGene has limitations; for example, deletion, in-
sertion, and frame-shift mutations are difficult to de-
tect. Although a capillary sequencer can detect ap-
proximately 100% of mutations, the EpiGene can de-
tect only about 90% of mutations. Because epilepsy is 
a syndromic disease that includes many phenotypes, 
numerous genes may contribute to the occurrence of 
epilepsy. Thus, the EpiGene is a powerful tool because 
it can simultaneously identify many genes in a patient. 
At present, costs for identification of mutations may be 
the same. Currently, we are testing the performance of 
a new version of EpiGene that contains 35 genes, in-
cluding genes responsible for the side effects of AEDs; 
this approach will significantly decrease the net cost 
to perform individualized medicine for epilepsy. The 
same preparation time is required for the EpiGene and 
capillary sequencer. However the EpiGene can simul-
taneously identify 14 kinds of gene’s mutations, while 
the capillary sequencing approach requires 14 sepa-
rate assays for a patient with unknown gene mutation. 
Recently, a next-generation sequencer became available. 
Although this next-generation sequencer can accurate-
ly detect mutations, its cost is too high for widespread 
clinical use. Our results indicate that the EpiGene chip 
is useful in clinical settings at least for screening pur-
poses, because it can simultaneously and efficiently de-
tect several gene mutations in a patient.
Frontal lobe epilepsy usually responds to carbam-
azepine, but frontal lobe epilepsy with an S284L muta-
tion in CHRNA4 responds to zonisamide but not car-
bamazepine; thus, the drug response is at least partly 
dependent on the kind of mutations (Zhu et al., 2008). 
Blumenfeld et al. (2008) reported that early treatment 
(before onset of epilepsy) of Wistar albino Glaxo rats 
of Rijswijk (WAG/Rij), a genetic animal model of ab-
sence epilepsy, with ethosuximide (300 mg/kg/day), 
resulted in a favorable outcome. Conceivably, it is pos-
sible to prevent epilepsy to some extent, by initiating 
treatment before the onset of epilepsy. For such an ear-
ly treatment, the early identification of individuals at 
risk is also crucial. The EpiGene is also applicable for 
this purpose. Thus, we can expect that a curative treat-
ment strategy for some patients with epilepsy may re-
sult from the early introduction of treatment based on 
genetic data generated with this DNA chip.
ConClusions
In conclusion, we developed a custom resequencing 
array, EpiGene, that can be used to detect epilepsy-re-
lated mutations. This array can be used to detect epi-
lepsy-related mutations at a high rate. Our results in-
dicate that this array could be used in clinical settings.
aCknowledgeMents
This study was conducted as part of a comprehensive 
project organized by the Epilepsy Genetic Study Group, 
Japan (chairperson, Sunao Kaneko) and was supported 
in part by Hirosaki University and a Grant-in-Aid for 
Scientific Research (S) (No. 16109006) and a Grant-in-
12 Takayuki Sugawara et al.
Aid for JSPS Fellows from the Ministry of Education, 
Culture, Sports, Science and Technology of Japan.
ConfliCt of interest
The authors have no potential conflicts of interest to 
declare.
referenCes
Blumenfeld H., Klein J.P., Schridde U., Vestal M., Rice T., 
Khera D.S. et al.: Early treatment suppresses the develop-
ment of spike-wave epilepsy in a rat model. Epilepsia, 2008, 
49: 400–409.
Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broe-
ckhoven C., De Jonghe P.: De novo mutations in the sodium-
channel gene SCN1A cause severe myoclonic epilepsy of infan-
cy. Am. J. Hum. Genet., 2001, 68: 1327–1332.
Claes L.R., Ceulemans B., Audenaert D., Deprez L., Jans-
en A., Hasaerts D. et al.: De novo KCNQ2 mutations in pa-
tients with benign neonatal seizures. Neurology, 2004, 63: 
2155–2158.
Dravet C., Bureau M., Guerrini R., Giraud N., Roger J.: Se-
vere myoclonic epilepsy in infants. In: J. Roger, M. Bureau, C. 
Dravet, F.E. Dreifuss, A. Perret, P. Wolf (Eds), Epileptic syn-
dromes in infancy, childhood and adolescence. 2nd ed., John 
Libbey & Company Ltd, London 1992, 75–88.
Fujiwara T., Sugawara T., Mazaki-Miyazaki E., Takahashi 
Y., Fukushima K., Watanabe M. et al.: Mutations of sodium 
channel alpha subunit type 1 (SCN1A) in intractable child-
hood epilepsies with frequent generalized tonic-clonic seizures. 
Brain, 2003, 126: 531–546.
Fukuma G., Oguni H., Shirasaka Y., Watanabe K., Miya-
jima T., Yasumoto S. et al.: Mutations of neuronal voltage-
gated Na+ channel alpha 1 subunit gene SCN1A in core severe 
myoclonic epilepsy in infancy (SMEI) and in borderline SMEI 
(SMEB). Epilepsia, 2004, 45: 140–148.
Gennaro E., Veggiotti P., Malacarne M., Madia F., Cecconi 
M., Cardinali S. et al.: Familial severe myoclonic epilepsy of 
infancy: truncation of Nav1.1 and genetic heterogeneity. Epi-
leptic Disord., 2003, 5: 21–25.
Hacia J.G.: Resequencing and mutational analysis using oligo-
nucleotide microarrays. Nat. Genet., 1999, 21: 42–47.
Kaneko S,, Yoshida S., Kanai K., Yasui-Furukori N., Iwa-
sa H.: Development of individualized medicine for epilepsy 
based on genetic information. Expert Rev. Clin. Pharmacol., 
2008, 1: 661–681.
Kearney J.A., Wiste A.K., Stephani U., Trudeau M.M., Siegel 
A., Ramachandran Nair R. et al.: Recurrent de novo muta-
tions of SCN1A in severe myoclonic epilepsy of infancy. Pedi-
atr. Neurol., 2006, 34: 116–120.
Kwan P., Brodie M.J.: Early identification of refractory epi-
lepsy. Engl. J. Med., 2000, 342: 314–319.
Madia F., Striano P., Gennaro E., Malacarne M., Paravidi-
no R., Biancheri R. et al.: Cryptic chromosome deletions in-
volving SCN1A in severe myoclonic epilepsy of infancy. Neu-
rology, 2006, 10: 1230–1235.
Mulley J.C., Nelson P., Guerrero S., Dibbens L., Iona X., Mc-
Mahon J.M. et al.: A new molecular mechanism for severe my-
oclonic epilepsy of infancy: exonic deletions in SCN1A. Neu-
rology, 2006, 67: 1094–1095.
Nabbout R., Gennaro E., Dalla Bernardina B., Dulac O., 
Madia F., Bertini E. et al.: Spectrum of SCN1A mutations 
in severe myoclonic epilepsy of infancy. Neurology, 2003, 24: 
1961–1967.
Nasir M., Olga V., Anthony M., Munir.: Exploring the 
genomic basis of pharmacoresistance in epilepsy: an integra-
tive analysis of large-scale gene expression profiling studies on 
brain tissue from epilepsy surgery. Hum. Mol. Genet., 2011, 
20: 4381–4394.
Ohmori I., Ouchida M., Ohtsuka Y., Oka E., Shimizu K.: 
Significant correlation of the SCN1A mutations and severe 
myoclonic epilepsy in infancy. Biochem. Biophys. Res. Com-
mun., 2002, 295: 17–23.
Ottman R., Hirose S., Jain S., Lerche H., Lopes-Cendes I., 
Noebels J.L. et al.: Genetic testing in the epilepsies-report of 
the ILAE Genetics Commission. Epilepsia, 2010, 51: 655–670.
Reid C.A., Berkovic S.F., Petrou S.: Mechanisms of human 
inherited epilepsies. Prog. Neurobiol., 2009, 87: 41–57.
Saitoh M., Shinohara M., Hoshino H., Kubota M., Amemi-
ya K., Takanashi J.L. et al.: Mutations of the SCN1A gene in 
acute encephalopathy. Epilepsia, 2012, 53: 558–564.
Shi L., Reid L.H., Jones W.D., Shippy R., Warrington J.A., 
Baker S.C. et al.: The MicroArray Quality Control (MAQC) 
project shows inter- and intraplatform reproducibility of 
gene expression measurements. Nat. Biotechnol., 2006, 24: 
1151–1161.
Steinlein O.K., Magnusson A., Stoodt J., Bertrand S., Wei-
land S., Berkovic S.F. et al.: An Insertion Mutation of the 
CHRNA4 gene in a family with autosomal dominant nocturnal 
frontal lobe epilepsy. Human. Mol. Genet., 1997, 6: 943–947.
Steinlein O.K., Mulley J.C., Propping P., Wallace R.H., Phil-
lips H.A., Sutherland G.R. et al.: A missense mutation in the 
neuronal nicotinic acetylcholine receptor alpha 4 subunit is as-
sociated with autosomal dominant nocturnal frontal lobe ep-
ilepsy. Nat. Genet., 1995, 11: 201–203.
Sugawara T., Tsurubuchi Y., Agarwala K.L., Ito M., Fuku-
ma G., Mazaki-Miyazaki E. et al.: A missense mutation of 
the Na+ channel alpha II subunit gene Na(v)1.2 in a patient 
13Gene chip for epilepsy diagnosis
with febrile and afebrile seizures causes channel dysfunction. 
Proc. Natl. Acad. Sci. USA, 2001, 98: 6384–6389.
Suls A., Claeys K.G., Goossens D., Harding B., Van Luijk 
R., Scheers S. et al.: Microdeletion involving the SCN1A gene 
may be common in SCN1A-mutation-negative SMEI patients. 
Hum. Mutat., 2006, 27: 914–920.
Wang J.W., Kurahashi H., Ishii A., Kojima T., Ohfu M., In-
oue T. et al.: Microchromosomal deletions involving SCN1A 
and adjacent genes in severe myoclonic epilepsy in infancy. 
Epilepsia, 2008, 49: 1528–1534.
Zhu G., Okada M., Yoshida S., Ueno S., Mori F., Takahara 
T. et al.: Rats harboring S284L Chrna4 mutation show atten-
uation of synaptic and extrasynaptic GABAergic transmis-
sion and exhibit the nocturnal frontal lobe epilepsy phenotype. 
J. Neurosci., 2008, 28: 12465–12476.
•
